Clinical effects of Helicobacter pylori outside the stomach

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 4, 2014, Pages 234-242

  Franceschi, Francesco ^a   Zuccalà, Giuseppe ^a   Roccarina, Davide ^a   Gasbarrini, Antonio ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE PANCREATITIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COLORECTAL CANCER; DEGENERATIVE DISEASE; DIABETES MELLITUS; EAR NOSE THROAT DISEASE; ENDOCRINE DISEASE; EYE DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEMATOLOGIC DISEASE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; IDIOPATHIC IRON DEFICIENCY ANEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IRON DEFICIENCY ANEMIA; ISCHEMIC HEART DISEASE; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC SYNDROME X; MIGRAINE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PANCREAS CANCER; PREECLAMPSIA; PREVALENCE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RESPIRATORY TRACT DISEASE; REVIEW; COMPLICATION; CYANOCOBALAMIN DEFICIENCY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANEMIA, IRON-DEFICIENCY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; NEURODEGENERATIVE DISEASES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; VITAMIN B 12 DEFICIENCY;

EID: 84898012170     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.243     Document Type: Review

References (119)

1. Franceschi, F., Genta, R. M. & Sepulveda, A. R. Gastric mucosa: Long-Term outcome after cure of Helicobacter pylori infection. J. Gastroenterol. 37 (Suppl. 13), 17-23 (2002).
2. Dooley, C. P. et al. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N. Engl. J. Med. 321, 1562-1566 (1989).
3. Calvet, X., Ramirex Lazaro, M. J., Lehours, P. & Megraud, F. Diagnosis and epidemiology of Helicobacter pylori infection. Helicobacter 18 (Suppl. 1), 5-11 (2013).
4. Moyaert, H. et al. Extragastric manifestations of Helicobacter pylori infection: Other Helicobacters. Helicobacter 13 (Suppl. 1), 47-57 (2008).
5. Figura, N. et al. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 15 (Suppl. 1), 60-68 (2010).
6. Mendall, M. A. et al. Relation of Helicobacter pylori infection and coronary heart disease. Br. Heart J. 71, 437-439 (1994).
7. Whincup, P. et al. Prospective study of potentially virulent strains of Helicobacter pylori and coronary heart disease in middle-Aged men. Circulation 101, 1647-1652 (2000).
8. Rathbone, B., Martin, D., Stephens, J., Thompson, J. R. & Samani, N. J. Helicobacter pylori seropositivity in subjects with acute myocardial infarction. Heart 76, 308-311 (1996).
9. Pasceri, V. et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 97, 1675-1679 (1998).
10. Pasceri, V. et al. Virulent strains of Helicobacter pylori and vascular diseases: A meta-Analysis. Am. Heart J. 151, 1215-1222 (2006).
11. Pellicano, R., Mladenova, I., Broutet, N., Salmi, L. R. & Mégraud, F. Is there an association between Helicobacter pylori infection and coronary heart disease? Eur. J. Epidemiol. 15, 611-619 (1999).
12. Franceschi, F. et al. CagA antigen of Helicobacter pylori and coronary instability: Insight from a clinico-pathological study and a meta-Analysis of 4241 cases. Atherosclerosis 202, 535-542 (2009).
13. Carter, A. M. et al. The influence of Helicobacter pylori status on circulating levels of the coagulation factors fibrinogen, von Willebrand factor, factor VII, and factor VIII. Helicobacter 1, 65-69 (1996).
14. Satoh, H., Saijo, Y., Yoshioka, E. & Tsutsui, H. Helicobacter pylori infection is a significant risk for modified lipid profile in Japanese male subjects. J. Atheroscler. Thromb. 17, 1041-1048 (2010).
15. Jia, E. Z. et al. Helicobacter pylori infection is associated with decreased serum levels of high density lipoprotein, but not with the severity of coronary atherosclerosis. Lipids Health Dis. 8, 59 (2009).
16. Kountouras, J., Polyzos, S. A., Deretzi, G., Katsinelos, P. & Kyriakou, P. Helicobacter pylori infection and the risk for cardiovascular disease. Eur. J. Intern. Med. 22, e146-e147 (2011).
17. Harvey, R. et al. Effect of Helicobacter pylori infection on blood pressure: A community based cross sectional study. BMJ 323, 264-265 (2001).
18. Liu, L. et al. Pathogen burden in essential hypertension. Circ. J. 71, 1761-1764 (2007).
19. Vahdat, K. et al. Association of pathogen burden and hypertension: The Persian Gulf Healthy Heart Study. Am. J. Hypertens. 26, 1140-1147 (2013).
20. Migneco, A. et al. Eradication of Helicobacter pylori infection improves blood pressure values in patients affected by hypertension. Helicobacter 8, 585-589 (2003).
21. Takenaka, R. et al. Helicobacter pylori heat-shock protein 60 induces inflammatory responses through the Toll-like receptor-Triggered pathway in cultured human gastric epithelial cells. Microbiology 150, 3913-3922 (2004).
22. Lenzi, C. et al. H. pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease. World J. Gastroenterol. 12, 7815-7820 (2006).
23. Birnie, D. H. et al. Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur. Heart J. 19, 387-394 (1998).
24. Bourantas, C. V., Garcia-Garcia, H. M., Diletti, R., Muramatsu, T. & Serruys, P. W. Early detection and invasive passivation of future culprit lesions: A future potential or an unrealistic pursuit of chimeras? Am. Heart J. 165, 869-881.e4 (2013).
25. Franceschi, F. et al. Cross-reactivity of anti-CagA antibodies with vascular wall antigens: Possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation 106, 430-434 (2002).
26. Rozankociv, P. B. et al. Influence of CagA-positive Helicobacter pylori strains on atherosclerotic carotid disease. J. Neurol. 258, 753-761 (2011).
27. Wang, Z. W. et al. Helicobacter pylori infection contributes to high risk of ischemic stroke: Evidence from a meta-Analysis. J. Neurol. 259, 2527-2537 (2012).
28. De Bastiani, R. et al. High prevalence of Cag A positive H. pylori strains in ischemic stroke: A primary care multicenter study. Helicobacter 13, 274-277 (2008).
29. Chen, B. F. et al. Relationship between Helicobacter pylori infection and serum interleukin 18 in patients with carotid atherosclerosis. Helicobacter 18, 124-128 (2013).
30. Corcoran, P. A. et al. The effect of different strains of Helicobacter pylori on platelet aggregation. Can. J. Gastroenterol. 21, 367-370 (2007).
31. Chen, Y., Segers, S. & Blaser, M. J. Association between Helicobacter pylori and mortality in the NHANES III study. Gut 62, 1262-1269 (2013).
32. Cremonini, F., Gabrielli, M., Gasbarrini, G., Pola, P. & Gasbarrini, A. The relationship between chronic H. pylori infection, CagA seropositivity and stroke: Meta-Analysis. Atherosclerosis 173, 253-259 (2004).
33. Shenoy, V., Kanasaki, K. & Kalluri, R. Pre-eclampsia: Connecting angiogenic and metabolic pathways. Trends Endocrinol. Metab. 21, 529-536 (2010).
34. Steegers E. A. et al. Pre-eclampsia. Lancet 376, 631-644 (2010).
35. Cardaropoli, S., Rolfo, A., Piazzese, A., Ponzetto, A. & Todros, T. Helicobacter pylori's virulence and infection persistence define pre-eclampsia complicated by fetal growth retardation. World J. Gastroenterol. 17, 5156-5165 (2011).
36. Franceschi, F. et al. Antibodies anti-CagA cross-react with trophoblast cells: A risk factor for pre-eclampsia? Helicobacter 17, 426-434 (2012).
37. Gasbarrini, A., Serricchio, M., Tondi, P., Gasbarrini, G. & Pola, P. Association of Helicobacter pylori infection with primary Raynaud phenomenon. Lancet 348, 966-967 (1996).
38. Gasbarrini, A. et al. Helicobacter pylori eradication ameliorates primary Raynaud's phenomenon. Dig. Dis. Sci. 43, 1641-1645 (1998).
39. Gasbarrini, A. et al. Association between Helicobacter pylori cytotoxic type I CagA-positive strains and migraine with aura. Cephalalgia 20, 561-565 (2000).
40. Faraji, F., Zarinfar, N., Zanjani, A. T. & Morteza, A. The effect of Helicobacter pylori eradication on migraine: A randomized, double blind, controlled trial. Pain Physician 15, 495-498 (2012).
41. Tunca, A., Ardiçoglu, Y., Kargili, A. & Adam, B. Migraine, Helicobacter pylori, and oxidative stress. Helicobacter 12, 59-62 (2007).
42. Marignani, M. et al. Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection. Scand. J. Gastroenterol. 32, 617-622 (1997).
43. Yuan, W. et al. Iron deficiency anemia in Helicobacter pylori infection: Meta-Analysis of randomized controlled trials. Scand. J. Gastroenterol. 45, 665-676 (2010).
44. Huang, X. et al. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgrad. Med. J. 86, 272-278 (2010).
45. Huang, X. et al. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgrad. Med. J. 86, 272-278 (2010).
46. Franceschi, F. & Gasbarrini, A. Helicobacter pylori and extragastric diseases. Best Pract. Res. Clin. Gastroenterol. 21, 325-334 (2007).
47. Gasbarrini, A. et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 352, 878 (1998).
48. Tsumoto, C. et al. Long-Term efficacy of Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura: 7 year follow-up prospective study. Ann. Hematol. 88, 789-793 (2009).
49. Veneri, D. et al. Analysis of B and T cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: Correlation with Helicobacter pylori infection and response to eradication treatment. Platelets 16, 307-311 (2005).
50. Veneri, D., Krampera, M. & Franchini, M. High prevalence of sustained remission of idiopathic thrombocytopenic purpura after Helicobacter pylori eradication: A long-Term follow-up study. Platelets 16, 117-119 (2005).
51. Veneri, D. et al. Idiopathic thrombocytopenic purpura, Helicobacter pylori infection, and HLA class II alleles. Blood 100, 1925-1926 (2002).
52. Godeau, B. & Michel, M. Treatment of chronic immune thrombocytopenic purpura in adults. Ann. Hematol. 89 (Suppl), 55-60 (2010).
53. Franceschi, F., Christodoulides, N., Kroll, M. H. & Genta, R. M. Helicobacter pylori and idiopathic thrombocytopenic purpura. Ann. Intern. Med. 140, 766-767 (2004).
54. Diamantidis, M. D. et al. High prevalence of Helicobacter pylori infection in Greek patients with myelodysplastic syndromes. Acta Haematol. 124, 141-149 (2010).
55. Malik, A. A., Ganti, A. K., Potti, A., Levitt, R. & Hanley, J. F. Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. Am. J. Gastroenterol. 97, 1371-1374 (2002).
56. Soler, J. A. et al. H. pylori eradication does not reduce paraprotein levels in monoclonal gammopathy of unknown significance (MGUS): A prospective cohort study. Ann. Hematol. 88, 769-773 (2009).
57. Asadi-Pooya, A. A., Dehghani, S. M., Petramfar, P., Emami, M. & Mahmoodi, M. Helicobacter pylori infection in patients with epilepsy. Seizure 21, 21-23 (2012).
58. Long, Y. et al. Helicobacter pylori infection in neuromyelitis optica and multiple sclerosis. Neuroimmunomodulation 20, 107-112 (2012).
59. Yoshimura, S. et al. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-Aquaporin 4 antibody status. J. Neurol. Neurosurg. Psychiatry 84, 29-34 (2013).
60. Kountouras, J. et al. Potential implications of Helicobacter pylori-related neutrophil-Activating protein. World J. Gastroenterol. 18, 489-490 (2012).
61. Kountouras, J. et al. Aquaporin 4, Helicobacter pylori and potential implications for neuromyelitis optica. J. Neuroimmunol. 263, 162-163 (2013).
62. Nielsen, H. H., Qiu, J., Friis, S., Wermuth, L. & Ritz, B. Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur. J. Neurol. 19, 864-869 (2012).
63. Dobbs, S. M. et al. Differential effect of Helicobacter pylori eradication on time-Trends in brady/hypokinesia and rigidity in idiopathic parkinsonism. Helicobacter 15, 279-294 (2010).
64. Kountouras, J. et al. Five-year survival after Helicobacter pylori eradication in Alzheimer disease patients. Cogn. Behav. Neurol. 23, 199-204 (2010).
65. Roubaud-Baudron, C., Krolak-Salmon, P., Quadrio, I., Megraud, F. & Salles N. Impact of chronic Helicobacter pylori infection on Alzheimer's disease: Preliminary results. Neurobiol. Aging 33, 1009.e11-19 (2012).
66. Roubaud Baudron, C. et al. Does Helicobacter pylori infection increase incidence of dementia? The Personnes Agees QUID Study. J. Am. Geriatr. Soc. 61, 74-78 (2013).
67. Beydoun, M. A., Beydoun, H. A., Shroff, M. R., Kitner-Triolo, M. H. & Zonderman, A. B. Helicobacter pylori seropositivity and cognitive performance among US adults: Evidence from a large national survey. Psychosom. Med. 75, 486-496 (2013).
68. Katan, M. et al. Infectious burden and cognitive function: The Northern Manhattan Study. Neurology 80, 1209-1215 (2013).
69. Zhou, X., Wu, J. & Zhang, G. Association between Helicobacter pylori and asthma: A meta-Analysis. Eur. J. Gastroenterol. Hepatol. 25, 460-468 (2013).
70. Oertli, M. & Müller, A. Helicobacter pylori targets dendritic cells to induce immune tolerance, promote persistence and confer protection against allergic asthma. Gut Microbes 3, 566-571 (2012).
71. Deshpande, N. et al. Helicobacter pylori IgG antibodies in aqueous humor and serum of subjects with primary open angle and pseudo-exfoliation glaucoma in a South Indian population. J. Glaucoma 17, 605-610 (2008).
72. Zavos, C. et al. Histological presence of Helicobacter pylori bacteria in the trabeculum and iris of patients with primary open-Angle glaucoma. Ophthalmic Res. 47, 150-156 (2012).
73. Zullo, A. et al. Glaucoma and Helicobacter pylori: Eyes wide shut? Dig. Liver Dis. 44, 627-628 (2012).
74. Pajić-Penavić, I., Danić, D., Maslovara, S. & Gall Trošelj, K. Absence of Helicobacter pylori in healthy laryngeal mucosa. J. Laryngol. Otol. 126, 196-199 (2012).
75. Gong, H. et al. Helicobacter pylori infection of the larynx may be an emerging risk factor for laryngeal squamous cell carcinoma. Clin. Transl. Oncol. 14, 905-910 (2012).
76. Ki, M. R. et al. Helicobacter pylori accelerates hepatic fibrosis by sensitizing transforming growth factor β1 induced inflammatory signaling. Lab. Invest. 90, 1507-1516 (2010).
77. Le Roux-Goglin, E. et al. Helicobacter infection induces podosome assembly in primary hepatocytes in vitro. Eur. J. Cell Biol. 91, 161-170 (2012).
78. Polyzos, S. A. et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism 62, 121-126 (2013).
79. Esmat, G., El-Bendary, M., Zakarya, S., Ela, M. A. & Zalata, K. Role of Helicobacter pylori in patients with HCV-related chronic hepatitis and cirrhosis with or without hepatocellular carcinoma: Possible association with disease progression. J. Viral Hepat. 19, 473-479 (2012).
80. Sakr, S. A., Badrah, G. A. & Sheir, R. A. Histological and histochemical alterations in liver of chronic hepatitis C patients with Helicobacter pylori infection. Biomed. Pharmacother. 67, 367-374 (2013).
81. Hu, B. L., Wang, H. Y. & Yang, G. Y. Association of Helicobacter pylori infection with hepatic encephalopathy risk: A systematic review. Clin. Res. Hepatol. Gastroenterol. http://dx.doi.org/10.1016/j.clinre.2013.05.004.
82. Kountouras, J., Zavos, C. & Deretzi, G. Helicobacter pylori might contribute to persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin. Gastroenterol. Hepatol. 9, 624 (2011).
83. Kountouras, J. et al. Helicobacter pylori induced cognitive dysfunction might be associated with falls and fractures in cirrhosis. Hepatology 57, 1284 (2013).
84. Kountouras, J., Zavos, C. & Chatzopoulos, D. A concept on the role of Helicobacter pylori infection in autoimmune pancreatitis. J. Cell. Mol. Med. 9, 196-207 (2005).
85. Shinji, A. et al. Autoimmune pancreatitis is closely associated with gastric ulcer presenting with abundant IgG4-bearing plasma cell infiltration. Gastrointest. Endosc. 59, 506-511 (2004).
86. Guarneri, F., Guarneri, C. & Benvenga, S. Helicobacter pylori and autoimmune pancreatitis: Role of carbonic anhydrase via molecular mimicry? J. Cell. Mol. Med. 9, 741-744 (2005).
87. Okazaki, K., Uchida, K. & Fukui, T. Recent advances in autoimmune pancreatitis: Concept, diagnosis, and pathogenesis. J. Gastroenterol. 43, 409-418 (2008).
88. Frulloni, L., et al. Identification of a novel antibody associated with autoimmune pancreatitis. N. Engl. J. Med. 361, 2135-2142 (2009).
89. Takayama, S., Takahashi, H., Matsuo, Y., Okada, Y. & Manabe, T. Effects of Helicobacter pylori infection on human pancreatic cancer cell line. Hepatogastroenterology 54, 2387-2391 (2007).
90. de Martel, C. et al. Helicobacter pylori infection and development of pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 17, 1188-1194 (2008).
91. Risch, H. A., Yu, H., Lu, L. & Kidd, M. S. ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: A case-control study. J. Natl Cancer Inst. 102, 502-505 (2010).
92. Risch, H. A. Pancreatic cancer: Helicobacter pylori colonization, N nitrosamine exposures, and ABO blood group. Mol. Carcinog. 51, 109-118 (2012).
93. Risch, H. A. et al. ABO blood group and risk of pancreatic cancer: A study in Shanghai and meta-Analysis. Am. J. Epidemiol. 177, 1326-1337 (2013).
94. Malfertheiner, P., Selgrad, M. & Bornschein, J. Helicobacter pylori: Clinical management. Curr. Opin. Gastroenterol. 28, 608-614 (2012).
95. Kountouras, J., Kapetanakis, N., Zavos, C. & Romiopoulos, I. Impact of Helicobacter pylori infection on normal colorectal mucosa, adenomatous polyps and the adenocarcinoma sequence. Colorectal Dis. http://dx.doi.org/10.1111/ codi.12356.
96. Machida-Montani, A. et al. Atrophic gastritis, Helicobacter pylori, and colorectal cancer risk: A case-control study. Helicobacter. 12, 328-332 (2007).
97. Zhang, Y., Hoffmeister, M., Weck, M. N., Chang Claude, J. & Brenner, H. Helicobacter pylori infection and colorectal cancer risk: Evidence from a large population-based case-control study in Germany. Am. J. Epidemiol. 175, 441-450 (2012).
98. Wu, Q., Yang, Z. P., Xu, P., Gao, L. C. & Fan, D. M. Association between Helicobacter pylori infection and the risk of colorectal neoplasia: A systematic review and meta-Analysis. Colorectal Dis. 15, e352-e364 (2013).
99. Sonnenberg, A. & Genta, R. M. Helicobacter pylori is a risk factor for colonic neoplasms. Am. J. Gastroenterol. 108, 208-215 (2013).
100. Zhou, X., Zhang, C., Wu, J. & Zhang, G. Association between Helicobacter pylori infection and diabetes mellitus: A meta-Analysis of observational studies. Diabetes Res. Clin. Pract. 99, 200-208 (2013).
101. Jeon, C. Y. et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care 35, 520-525 (2012).
102. Shin, D. W. et al. Association between metabolic syndrome and Helicobacter pylori infection diagnosed by histologic status and serological status. J. Clin. Gastroenterol. 46, 840-845 (2012).
103. Chen, Y. & Blaser, M. J. Association between gastric Helicobacter pylori colonization and glycated hemoglobin levels. J. Infect. Dis. 205, 1195-1202 (2012).
104. Akanuma, M. et al. Influence of Helicobacter pylori eradication on the management of type 2 diabetes. Hepatogastroenterology 59, 641-645 (2012).
105. Tseng, C. H. Diabetes, insulin use and Helicobacter pylori eradication: A retrospective cohort study. BMC Gastroenterol. 9, 12-46 (2012).
106. Chung, G. E. et al. Helicobacter pylori seropositivity in diabetic patients is associated with microalbuminuria. World J. Gastroenterol. 19, 97-102 (2013).
107. Zhou, X., Zhang, C., Wu, J. & Zhang, G. Association between Helicobacter pylori infection and diabetes mellitus: A meta-Analysis of observational studies. Diabetes Res. Clin. Pract. 99, 200-208 (2013).
108. Candelli, M. et al. High reinfection rate of Helicobacter pylori in young type 1 diabetic patients: A three-year follow-up study. Eur. Rev. Med. Pharmacol. Sci. 16, 1468-1472 (2012).
109. Shi, W., Liu, W., Zhou, X., Ye, F. & Zhang, G. Associations of Helicobacter pylori infection and cytotoxin-Associated gene A status with autoimmune thyroid diseases: A meta-Analysis. Thyroid 23, 1294-1300 (2013).
110. Franceschi, F. et al. Helicobacter pylori infection in patients with Hashimoto's thyroiditis. Helicobacter 9, 369 (2004).
111. Ram, M. et al. Helicobacter pylori serology in autoimmune diseases-fact or fiction? Clin. Chem. Lab. Med. 51, 1075-1082 (2012).
112. Cicconi, V. et al. Disappearance of antiphospholipid antibodies syndrome after Helicobacter pylori eradication. Am. J. Med. 111, 163-164 (2001).
113. Tüzün, Y., Keskin, S. & Kote, E. The role of Helicobacter pylori infection in skin diseases: Facts and controversies. Clin. Dermatol. 28, 478-482 (2010).
114. Di Campli, C. et al. Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. Dig. Dis. Sci. 43, 1226-1229 (1998).
115. Ojetti, V. et al. Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria. Int. Arch. Allergy Immunol. 125, 66-72 (2001).
116. Magen, E. & Mishal, J. Possible benefit from treatment of Helicobacter pylori in antihistamine-resistant chronic urticaria. Clin. Exp. Dermatol. 38, 7-12 (2013).
117. El-Khalawany, M. et al. Role of Helicobacter pylori in common rosacea subtypes: A genotypic comparative study of Egyptian patients. J. Dermatol. 39, 989-995 (2012).
118. Malfertheiner, P. et al. European Helicobacter Study Group. Management of Helicobacter pylori infection-The Maastricht IV/ Florence Consensus Report. Gut 61, 646-664 (2012).
119. Vitale, G. et al. Nutritional aspects of Helicobacter pylori infection. Minerva Gastroenterol. Dietol. 57, 369-377 (2011).